Coffee, tea consumption associated with reduced risk of diabetes
NEW YORK Drinking more coffee (regular or decaffeinated) or tea appears to lower the risk of developing Type 2 diabetes, according to an analysis of previous studies reported in the Dec. 14/28 issue of Archives of Internal Medicine.
Rachel Huxley, D.Phil, of The George Institute for International Health, University of Sydney, Australia, and colleagues identified 18 studies involving 457,922 participants and assessing the association between coffee consumption and diabetes risk published between 1966 and 2009.
Six studies involving 225,516 individuals also included information about decaffeinated coffee, whereas seven studies with 286,701 participants reported on tea consumption.
When the authors combined and analyzed the data, they found that each additional cup of coffee consumed in a day was associated with a 7% reduction in the excess risk of diabetes, while individuals who drank three to four cups per day had an approximately 25% lower risk than those who drank between zero and two cups per day.
In addition, in the studies that assessed decaffeinated coffee consumption, those who drank more than three to four cups per day had about a one-third lower risk of diabetes than those who drank none. Those who drank more than three to four cups of tea had a one-fifth lower risk than those who drank no tea.
Recent reports projected the number of people in the United States with diabetes will nearly double over the next 25 years, and costs for related treatments will triple.
Industry coalition reissues advisory against use of dietary supplements as swine flu remedy, cure
NEW YORK If there’s a huckster swindling supplements as the latest cure-all, turns out it’s not a supplement they’re swindling after all. If not an illicit pharmaceutical outright, it’s at the very least a mismarketed snake oil, and this band of supplement associations is helping to stamp those hucksters out.
That’s better news for brick-and-mortar retailers of supplement products than it is for any online retailers, because many of the supplements being marketed inappropriately are sold almost exclusively online or maybe in smaller specialty channels, but not in mass. That’s a matter of simple economics — it costs quite a bit of capital to feed a mass channel supply chain, and there aren’t any legitimate companies, supplier or retailer, that’d risk that kind of investment to sell an illegal product.
So the more these companies making such illegal claims as “Nature’s Swine Flu Cure,” or companies incorporating actual pharmaceuticals into products claiming to enhance performance, are outed as companies not to be trusted, and the more consumers associate those pitches as appearing only online, during late-night infomercials (not available in stores!) or through emails automatically routed to the junk mail box, the more community pharmacies become the go-to source for any supplement-related health information.
Pharmacogenomics in aisle 1?
Not quite, but the continued evolution of Kerr Drug’s Community Healthcare Center store concept certainly offers a glimpse into what role community pharmacy could play in the American healthcare system of the future—and it goes far beyond just medication therapy management. Like the deal CVS Caremark announced in November with Generation Health, pharmacogenomics, the study of how genetics influence drug response, represents the new frontier of community pharmacy. And it’s a brave new world out there, to be sure.
In fairness, pharmacogenomics has been a part of the specialty pharmacy business for some time. But projects like Kerr’s pilot with the University of North Carolina’s Eshelman School of Pharmacy, which will focus on patients taking Plavix, target the long-term savings generated by patients on traditional drug therapies (see related story). These types of programs will be instrumental in demonstrating community pharmacy’s value beyond simply dispensing; the idea that a $250 test performed at the local drug store potentially could save $50,000 or more in upstream costs.
“We are at the doorstep not only of a new store, but also the future of community pharmacy,” Kerr Drug president and CEO Tony Civello told guests at the grand opening.
At the same time, on a much larger scale, the CVS Caremark-Generation Health deal will give big healthcare payers a front-row seat as it demonstrates the value of pharmacogenomics, offering PBM customers a chance to offer testing programs around drugs used to treat cancer, HIV and heart disease (see related story). CVS actually took a minority position in the privately held company, and chief medical officer Troyen Brennan will serve on Generation’s board of directors. So you can say the folks in Woonsocket hold quite a bit of stock in this whole area of personalized medicine.
That CVS is showing its leadership in an area like pharmacogenomics is not surprising. It is a company that has invested considerably in recent years to build a future beyond simply dispensing pharmaceuticals. But stories like what Kerr is doing in examination room No. 5 in its new Community Healthcare Center are an important reminder of the innovation and leadership that continues to come out of Chapel Hill, N.C.
They also are a sign that maybe the future of pharmacy doesn’t have one of those “you must be this size to ride this ride” signs. It’s not that size isn’t important, so much as maybe there is more than one way to measure it. Maybe, big ideas count, too.